Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

Cancer Research Catalyst features informative posts on cancer prevention for media41918410/20/2014 4:35:46 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx15False2014-10-20T16:30:00Z<div class="ExternalClass252F1E5981D24F83B09DDE238C5074DF"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features two recent posts on cancer prevention research that you might find interesting and informative. </p><p>Graham A. Colditz, MD, DrPH, Niess-Gain Professor of Surgery, professor of medicine, and associate director of prevention and control at the Alvin J. Siteman Cancer Center at the Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, provides a <a href="http&#58;//blog.aacr.org/youthful-approach-expanding-reach-breast-cancer-prevention/" target="_blank">guest post</a> on breast cancer prevention. Colditz, who recently received the <a href="/Newsroom/Pages/News-Release-Detail.aspx?ItemID=607">2014 AACR Award for Outstanding Achievement in Cancer Prevention Research</a>, stresses the importance of early breast cancer prevention beginning in childhood.</p><p>On the opposite spectrum, Robert L. Strausberg, PhD, executive director of collaborative sciences at the Ludwig Institute for Cancer Research, <a href="http&#58;//blog.aacr.org/addressing-cancer-graying-america/" target="_blank">discusses</a> cancer prevention among the United States’ aging population, a demographic that is growing as life expectancies increase.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Molecular Targets and Cancer Therapeutics 26th EORTC-NCI-AACR SYMPOSIUM40021810/13/2014 2:30:36 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx14False2014-10-13T13:00:00ZNov. 18-21, 2014; Barcelona, Spain <div class="ExternalClass025DC22138DB4917B8401E37F576B3D2"><p>​Journalists are invited to attend this meeting held by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">Registration</a> is free for credentialed journalists. </p><p>The <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=18">EORTC-NCI-AACR Symposium</a> is the premier scientific forum for researchers developing the cancer drugs of the future. Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has led to the development of numerous new agents, &quot;designer&quot; diagnostics, prognostic tests, &quot;smart&quot; drugs, innovative targets for clinical trials, and other new ways of tackling cancer. Around 2,200 international cancer experts will be attending the meeting to discuss the latest breakthroughs in preclinical and clinical research to facilitate further advances against cancer.</p><p>The majority of the abstracts <a href="http&#58;//www.ecco-org.eu/ENA" target="_blank">will go online</a> at noon Central European Time (CET), Oct. 30, 2014. Some, including late-breaking abstracts and those that form part of the official media program, will only be embargoed and published online on the day of presentation.</p><p>Examples of highlighted research include&#58; </p><ul><li>First report from a phase I clinical trial of a first-in-class drug, AG-120, in patients with advanced hematologic malignancies with the IDH1 mutation. </li><li>Updated interim results from the ongoing phase II clinical trial examining the potential of rociletinib, a new drug that targets mutant EGFR, including theT790M mutant, as a treatment for non-small cell lung cancer.</li><li>Early results of the safety and efficacy of ASP 8273, an inhibitor of mutant EGFR, including the T790M mutant.</li><li>Report on the safety and efficacy of a combination therapy (the BRAF V600 inhibitor encorafenib, the EGFR-targeted monoclonal antibody cetuximab, with or without the P13K inhibitor alpelisib) to treat patients with advanced colorectal cancer with the BRAF mutation.</li><li>Interim results from a phase II clinical trial testing a combination of bevacizumab and erlotinib as a treatment for metastatic papillary kidney cancer.</li><li>Preclinical science and updated results from ARMOR2, a phase II clinical trial testing galeterone in men with castration-resistant prostate cancer.</li><li>Results from a phase I clinical trial pioneering a new approach to treating HPV-related cervical cancer.</li></ul><p>Sessions are open to journalists and <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">registration information</a> is available online.</p><p>A media center with international phone and internet connections will be available.</p><p>The official language of the symposium is English and all press materials will be in English.</p><p><strong>For media queries about the symposium, contact&#58; </strong></p><p>Emma Mason, media consultant&#58;<br><a href="mailto&#58;wordmason@mac.com">wordmason@mac.com</a> <br>+44 (0) 7711 296 986</p><p>Jeremy Moore, American Association for Cancer Research<br><a href="mailto&#58;jeremy.moore@aacr.org267-250-5441">jeremy.moore@aacr.org<font color="#444444"><br></font>267-250-5441</a></p><p><strong>Accommodations&#58;</strong></p><p><a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Travel-and-Accommodation" target="_blank">Get information</a> on accommodations in Barcelona.</p></div>
2014 Turning the Tide Against Cancer National Conference Will Explore Policy Solutions to Pressing Challenges in Oncology37944010/6/2014 4:48:59 PM3http://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx13False2014-10-06T13:00:00ZNational conference to address how public policy can sustain innovation to turn the tide against cancer<div class="ExternalClassB16733CB116F4AB0B16EDA8BE610788D"><p>The Personalized Medicine Coalition, the American Association for Cancer Research, and Feinstein Kean Healthcare are convening the second national <a href="http&#58;//turningthetideagainstcancer.org/" target="_blank">Turning the Tide Against Cancer Through Sustained Medical Innovation</a> conference to continue the ongoing dialogue around policy solutions that align with scientific advances and support innovation in cancer research and care, while addressing the issue of rising health care costs.</p><p>The conference will bring together leaders from across the scientific, clinical, regulatory, industry, and patient communities to discuss actionable policies that support the shift to patient-centric cancer research and care and address issues of value and cost in oncology. The policy options discussed at the conference will inform the ongoing activities of the Turning the Tide Against Cancer initiative to ensure that future investments in research and care delivery will address the evolving demands of the cancer community.</p><p dir="ltr" style="margin-right&#58;0px;"><strong>WHEN</strong>&#58;&#160;<br>Thursday, Oct. 9, 2014<br>8&#58;30 a.m. – 4 p.m. EDT</p><p><strong>LOCATION</strong>&#58;&#160;<br>Knight Conference Center at the Newseum <br>555 Pennsylvania Ave., NW<br>Washington, DC&#160; 20001</p><p><strong>TWITTER</strong>&#58; &#160;<br><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23T3cancer" target="_blank">#T3cancer</a></p><p><strong>REGISTRATION INFORMATION</strong>&#58; <br>Registration for members of the media is free. Please <a href="mailto&#58;amanda.guisbond@fkhealth.com" target="_blank">email</a> or call Amanda Guisbond (617-761-6797) for press credentials.&#160; </p><p><strong>SPEAKERS</strong>&#58;</p><ul><li><strong>Amy Abernethy, MD, PhD</strong>, professor of medicine, Duke University School of Medicine; chief medical officer and senior vice president of oncology, Flatiron Health Inc.;</li><li><strong>Anna Barker, PhD</strong>, co-director, Complex Adaptive Systems Initiative; president and director, National Biomarker Development Alliance; professor, School of Life Sciences, Arizona State University;</li><li><strong>Tanisha V. Carino, PhD</strong>, executive vice president, Avalere Health;</li><li><strong>John J. Castellani</strong>, president and chief executive officer, Pharmaceutical Research and Manufacturers of America; </li><li><strong>Tony Coelho</strong>, former member, U.S. House of Representatives; chairman, Partnership to Improve Patient Care;</li><li><strong>Newton F. Crenshaw</strong>, vice president, North American Oncology Commercial Operations, Global Business Development, and Advocacy,&#160; Eli Lilly and Company;</li><li><strong>William S. Dalton, PhD, MD</strong>, chief executive officer, M2Gen; director, DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute; </li><li><strong>Stephen L. Eck, MD, PhD</strong>, vice president, global head of oncology medical sciences, Astellas Pharma Global Development;</li><li><strong>Shelley Fuld Nasso, MPP</strong>, chief executive officer, National Coalition for Cancer Survivorship;</li><li><strong>Patricia J. Goldsmith</strong>, chief executive officer, CancerCare;</li><li><strong>Roy S. Herbst, MD, PhD</strong>, ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research, Yale Comprehensive Cancer Center and Yale School of Medicine;</li><li><strong>Linda House, RN, BSN, MSM</strong>, executive vice president, external affairs, Cancer Support Community;</li><li><strong>Robert J. Hugin</strong>, chairman and chief executive officer, Celgene Corporation;</li><li><strong>Suleika Jaouad</strong>, <em>The New York Times </em>Emmy<sup>®</sup> Award-winning columnist, “Life, Interrupted,” and cancer survivor;</li><li><strong>Paul G. Kluetz, MD</strong>, acting deputy office director, prostate cancer scientific liaison, Office of Hematology and Oncology Products, U.S. Food and Drug Administration;</li><li><strong>Michael Kolodziej, MD</strong>, national medical director, oncology solutions, office of the chief medical officer, Aetna;</li><li><strong>Jennifer Malin, MD, PhD</strong>, medical director for oncology for care management, WellPoint Inc.;</li><li><strong>Lee N. Newcomer, MD, MHA</strong>, senior vice president, oncology, genetics, and women’s health, UnitedHealthcare; </li><li><strong>Richard L. Schilsky, MD, FASCO</strong>, chief medical officer, American Society of Clinical Oncology; professor emeritus, University of Chicago;</li><li><strong>Lowell Schnipper, MD</strong>, Theodore W. and Evelyn G. Berenson professor, Department of Medicine, Harvard Medical School; chief, hematology/oncology, Beth Israel Deaconess Medical Center; clinical director, Beth Israel Deaconess Medical Center Cancer Center; and</li><li><strong>Jeff A. Walker, MBA</strong>, senior executive director for administration, Comprehensive Cancer Center and James Cancer Hospital/Solove Research Institute, The Ohio State University.</li></ul><p>&#160;</p><p><a href="http&#58;//www.turningthetideagainstcancer.org/" target="_blank">View</a> the full agenda. </p></div>
Cancer Research Catalyst features informative posts for media36672810/1/2014 1:17:12 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx12False2014-10-01T13:00:00Z<div class="ExternalClass23DC7DB06E1446C79B2A797FC9C28A75"><p><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features two recent posts on lung cancer research that you might find interesting and informative. </p><p>Fadlo R. Khuri, MD, deputy director for the Winship Cancer Institute of Emory University in Atlanta, provides a <a href="http&#58;//blog.aacr.org/lung-cancer-progress-made-yet/" target="_blank">guest post</a> on lung cancer research, highlighting the progress already made and the needs for the future, including an enhanced understanding of lung cancer origins in never-smokers and implementation of strong tobacco control programs.</p><p>Srivani Ravoori, PhD, AACR senior science writer, <a href="http&#58;//blog.aacr.org/findings-open-doors-rational-lung-cancer-treatment-strategies/" target="_blank">discusses</a> new findings on mutations and drug resistance that could lead to new treatment strategies for certain lung cancer patients. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit</a> the blog and subscribe. </p></div>
Sen. Dick Durbin, Sen. Amy Klobuchar, and NIH Director Francis Collins to Speak at Events in Support of Medical Research3301259/18/2014 9:21:27 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx11False2014-09-17T13:00:00Z<div class="ExternalClassEDC5706451214B4EA357F7F23CA6A1AC"><p><strong>What</strong><br>On Wednesday, Sept. 17, Senator Dick Durbin (D-IL) will sponsor and speak at an evening reception to celebrate the lifesaving research that the National Institutes of Health (NIH) supports. The event will also include remarks from Francis S. Collins, MD, PhD, director of the NIH, who will discuss the unprecedented scientific opportunities that exist today to markedly reduce human disease.</p><p>The next morning, three hundred organizations and institutions will come together for a breakfast to kick off the Rally for Medical Research Hill Day, during which more than 300 scientists, health professionals, and patient advocates will urge Congress to support increased federal funding for the NIH.</p><p>Speakers at the breakfast include&#58;</p><ul><li><strong>Margaret Foti, PhD, MD (hc)</strong><br>Chief Executive Officer, American Association for Cancer Research</li><li><strong>Senator Amy Klobuchar (D-MN)</strong></li><li><strong>Susan Mahony, PhD </strong><br>Senior Vice President, Eli Lilly and Company and President, Lilly Oncology</li></ul><p>&#160;</p><p>The speakers will discuss how medical research benefits patients and provide encouragement to the advocates and staff preparing for their day of advocacy on Capitol Hill. </p><p>“To accelerate continuous innovation against cancer, we need sustained research funding in the public sector – as well as in the private sector,” said Mahony, previewing her prepared remarks. “This is what fuels the collaboration between national research institutes, universities, industry, and the cancer treatment community – and this is what ultimately keeps us moving forward.”</p><p>The program will last approximately 40 minutes. </p><p><strong>When and where<br></strong><em>Reception to Celebrate Medical Research </em></p><ul><li>Wednesday, Sept. 17</li><li>5-7 p.m. ET</li><li>Russell Senate Office Building, Kennedy Caucus Room<br>2 Constitution Avenue NE<br>Washington, D.C. 20002</li></ul><p><em></em>&#160;</p><p><em>Rally for Medical Research Hill Day Breakfast</em></p><ul><li>Thursday, Sept. 18</li><li>Doors open at 7&#58;30 a.m. ET, speakers begin at 8 a.m. ET </li><li>Hyatt Regency Washington on Capitol Hill<br>400 New Jersey Avenue NW<br>Washington, D.C. 20001</li></ul><p><strong></strong>&#160;</p><p><strong>Contacts</strong><br>To register as press or arrange interviews with any of the speakers, please contact&#58;</p><p>Jeremy Moore<br>267-250-5441 (Cell)<br><a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a></p><p>Jeff Molter<br>267-210-3965 (Cell)<br><a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> </p></div>
American Association for Cancer Research to Release New Cancer Progress Report on Sept. 162719289/11/2014 9:19:52 PM3http://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx10False2014-09-02T14:00:00ZReport will be discussed during press teleconference and ABC News Twitter chat<div class="ExternalClassE89C436387EB43259DE6405BCA742D1D"><p style="text-decoration&#58;underline;"><strong>Press Teleconference, 10 a.m. ET</strong></p><p>The American Association for Cancer Research (AACR) will host a press teleconference summarizing the findings of the <em>AACR&#160;Cancer Progress Report 2014</em>. The speakers are&#58;</p><ul><li><strong>AACR President Carlos L. Arteaga, MD</strong><br>Director, Center for Cancer Targeted Therapies and director, Breast Program and SPORE, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee</li><li><strong>Jeffrey A. Engelman, MD, PhD</strong><br>Director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, and associate professor of medicine, Harvard Medical School, Boston, Massachusetts</li><li><strong>James (Rocky) Lagno</strong><br>Lung cancer survivor featured in the <em>AACR&#160;Cancer Progress Report 2014</em>, Epping, New Hampshire </li></ul><p>​Engelman will also discuss new findings to be published in the AACR journal <em>Clinical Cancer Research</em> regarding the treatment of ALK-mutant lung cancer. </p><p>To join the teleconference, use the following dial-in information&#58;</p><ul><li>1-866-297-6395 (U.S. toll-free)</li><li>1-847-944-7317 (U.S. toll)</li><li>Confirmation Number&#58; 37970987</li></ul><h4>&#160;</h4><p style="text-decoration&#58;underline;"><strong>ABC News Twitter Chat, 1 p.m. ET</strong></p><p>The AACR will join an ABC News Twitter chat on progress in cancer and the future of cancer research. The chat will be moderated by ABC News Medical Editor Richard Besser, MD.</p><p>Timothy Rebbeck, PhD, will tweet on behalf of the AACR. He is editor-in-chief of <em>Cancer Epidemiology, Biomarkers &amp; Prevention</em>, a journal of the AACR; associate director for population sciences at the Abramson Cancer Center of the University of Pennsylvania; and professor of biostatistics and epidemiology at Penn’s Perelman School of Medicine. More than 40 cancer centers from across the country have agreed to participate as well. </p><p>Follow the conversation on Twitter and join in&#58; <a href="https&#58;//twitter.com/search?q=%23abcDrBchat" target="_blank">#abcDrBchat</a>. Follow the AACR on Twitter&#58; <a href="http&#58;//www.twitter.com/aacr" target="_blank">@AACR</a>.</p><p>The Twitter chat will coincide with an ABC News Google+ Hangout. More details about the Hangout will be available soon.</p><p><strong style="text-decoration&#58;underline;">Media contacts</strong><br style="text-decoration&#58;underline;">Jeremy Moore<br>215-446-7109<br><a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a></p><p>Julia Gunther<br>215-446-6896<br><a href="mailto&#58;julia.gunther@aacr.org">julia.gunther@aacr.org</a></p><p>Lauren Riley<br>215-446-7155 <br><a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a></p><p>Jeff Molter<br>215-446-7233<br><a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> ​</p></div>
Cancer Research Catalyst Features AACR Press Programs45868/5/2014 4:53:17 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx9False2014-07-31T16:00:00Z<div class="ExternalClassFB50CA07019F46AF881121D8431EA5E0"><p><em>Cancer Research Catalyst</em>, the blog of the American Association for Cancer Research (AACR), features a new post this week on the AACR media relations programs conducted for scientific meetings. </p><p>The <a href="http&#58;//blog.aacr.org/aacrs-special-conference-series-makes-headlines/" target="_blank">post</a> details how partnerships between organizations help raise awareness via media outlets about the rising incidence of pancreatic cancer and innovative scientific research. </p><p>These posts are part of the continuing mission of Cancer Research Catalyst to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public.</p><p>Visit the blog at <a href="http&#58;//blog.aacr.org/" target="_blank">http&#58;//blog.aacr.org</a> and subscribe. </p></div>
Cancer Research Catalyst Features Informative Posts for Media 1630627/24/2014 5:06:43 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx8False2014-07-24T04:00:00Z<div class="ExternalClassA120B32A388B425FBDC43A4F8C9B5598"><p>​<em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a></em>, the blog of the American Association for Cancer Research (AACR), features two new posts this week on innovative science and opportunities for young researchers. <br><br>Srivani Ravoori, PhD, senior science writer, <a href="http&#58;//blog.aacr.org/exceptional-responder/" target="_blank">explains</a> the science behind exceptional responders, where a patient has a unique response to a cancer treatment due to their genetic makeup. <br><br>Karen Honey, PhD, senior managing editor for science communications, <a href="http&#58;//blog.aacr.org/supporting-early-career-cancer-researchers/" target="_blank">highlights</a> opportunities for young scientists to participate in AACR workshops that could shape the rest of their careers.<br><br>These posts are part of the continuing mission of Cancer Research Catalyst to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to our members and the public. <br><br>Visit the blog at <a href="http&#58;//blog.aacr.org/" target="_blank">http&#58;//blog.aacr.org</a> and subscribe. </p></div>
American Association for Cancer Research to Participate in Tomorrow’s Twitter Chat on the Promise of Immunotherapy45116/18/2014 7:22:54 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx3False2014-06-05T04:00:00Z<div class="ExternalClass296BB431DC69415DA7DAA44CD9E690F2"><p>​The American Association for Cancer Research (AACR) will partner with Time magazine, Mayo Clinic Cancer Center, and Cancer Research Institute for a Twitter chat titled “The Promise of Immunotherapy,” Wednesday, June 18, 1-2 p.m. ET. <br><br>Immunotherapy is a unique approach to cancer treatment that restores the immune system’s ability to detect and eliminate cancer cells. <br><br>Esteban Celis, MD, PhD, a member of the AACR Cancer Immunology Steering Committee and professor of medicine at Georgia Regents University Cancer Center, will represent the AACR on this Twitter chat, which will be moderated by Time magazine’s Senior Health Reporter Alice Park. <br><br>Follow the conversation on Twitter and join us&#58; <a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23CIMchat&amp;src=typd" target="_blank">#CIMchat</a><br><br>Follow the AACR on Twitter&#58; <a href="http&#58;//www.twitter.com/aacr" target="_blank">@AACR</a><br><br>For more information, please contact Jeremy Moore at <a href="mailto&#58;jeremy.moore@aacr.org" target="_blank">jeremy.moore@aacr.org</a> or 215-446-7109, or Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155.</p></div>
AACR to Host Two Press Teleconferences at Pancreatic Cancer Conference 45128/22/2014 1:30:18 AMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx4False2014-05-08T04:00:00Z<div class="ExternalClassAAF3F390810348FAA16DC418F4CCA4A1"><p>​NEW ORLEANS — The American Association for Cancer Research (AACR) will host two press teleconferences at its special conference on Pancreatic Cancer&#58; Innovations in Research and Treatment, May 18-21 at the Hyatt Regency New Orleans.<br><br>A press kit containing embargoed news releases and highlighted abstracts will be available to media May 13. <br> <br> <strong>First Teleconference</strong><br>The first teleconference will be held Monday, May 19, 10 a.m. CT. Reporters can dial in at 866-297-6395 (United States/Canada) or 847-944-7317 (international), and should offer confirmation code 37195596 when prompted. It will include&#58;&#160; </p><ul><li>Analyses projecting paradigm-shifting pancreatic cancer mortality rates;</li><li>Updated results of a phase Ib trial combining gemcitabine with a new radioimmunotherapy for metastatic pancreatic cancer;</li><li>Development and validation of a blood-based biomarker panel for detection of early-stage pancreatic cancer; and</li><li>Preclinical results indicating CD47 may be a therapeutic target for pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma.</li></ul><p> <strong>Second Teleconference</strong><br>On Wednesday, May 21, 10 a.m. CT, conference leaders David Tuveson, M.D., Ph.D., The Lustgarten Foundation and Cold Spring Harbor Laboratories; Christine Iacobuzio-Donahue, M.D., Memorial Sloan Kettering Cancer Center; and Alec Kimmelman, M.D., Ph.D., Dana-Farber Cancer Institute, will offer analysis of the conference, including discussion of exciting new research areas and potential treatment options. <br> <br>Reporters who join that press teleconference should dial 866-297-6395 (United States/Canada) or 847-944-7317 (international) and offer confirmation code 37264783 when prompted.&#160; </p><table align="center" class="mceItemTable" border="0"><tbody><tr><td><p> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<img src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" alt="" style="margin&#58;5px;" />&#160;&#160;&#160;<br>&#160;</p></td><td><h4> <a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23AACRPanCa14" target="_blank">#AACRPanCa14</a></h4></td></tr></tbody></table></div>